Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Apimeds Pharmaceuticals US, Inc. (APUS)

ASE · Drug Manufacturers - Specialty & Generic

$8.00+1.71 (+27.19%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$12.1M
P/E (TTM)
EPS
$-35.30
Div Yield
52W Range
$5.44–$59.70
Beta

Company overview

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Peers in Drug Manufacturers - Specialty & Generic

All in industry →

Recent press releases

Apimeds Pharmaceuticals US, Inc. has not issued a press release in this window.

SEC filings

All filings →

Apimeds Pharmaceuticals US, Inc. has not filed an SEC document in this window.

Apimeds Pharmaceuticals US, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
27,188 sh● NEW
58,992 sh0.0%
274,000 sh+9.6%
34,888 sh+13.4%
582 sh● NEW

People at Apimeds Pharmaceuticals US, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$402.4K
06/25
NI -$2.7M
09/25
NI -$1.8M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.14
Prior: $-0.26
Revenue sparkline